{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:49:24Z","timestamp":1776829764009,"version":"3.51.2"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of Review<\/jats:title>\n            <jats:p>Cutaneous T-Cell Lymphoma (CTCL) poses challenges both in diagnosis and prognosis. The purpose of this review is to address the role of profiling immune and non-immune cells in the tumor microenvironment (TME) as it provides information for better diagnosis, prognosis, biomarker discovery, and personalized treatment strategies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>Recent evidence suggests that the progression of CTCL is closely linked to the Tumor Microenvironment (TME) which comprises various cell types including immune cells, stromal cells, blood vessels, and the extracellular matrix. Cell profiling within the TME demonstrates the perplexity of intracellular communication of the different cell fates and their mediators as the disease progresses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>CTCL as a rare form of non-Hodgkin lymphoma often misdiagnosed due to its similarity to other skin conditions. It encompasses diseases like Mycosis fungoides (MF) and S\u00e9zary Syndrome (SS), with the latter being more severe. Advances in studying the TME have shown its pivotal role in CTCL progression, highlighting the need for comprehensive cell profiling to enhance diagnosis, prognosis, and treatment personalization.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11912-025-01646-6","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T19:09:51Z","timestamp":1741374591000},"page":"415-430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1365-0355","authenticated-orcid":false,"given":"Nikolaos A.","family":"Chinas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-6906","authenticated-orcid":false,"given":"Stella","family":"Kaliampou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-9152","authenticated-orcid":false,"given":"Vasiliki","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"21","key":"1646_CR1","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","volume":"113","author":"PT Bradford","year":"2009","unstructured":"Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064\u201373. https:\/\/doi.org\/10.1182\/blood-2008-10-184168.","journal-title":"Blood"},{"key":"1646_CR2","doi-asserted-by":"crossref","unstructured":"Sterry W, Mielke V. CD4\u2009+\u2009cutaneous T-cell lymphomas show the phenotype of helper\/inducer T cells (CD45RA-, CDw29+). J Invest Dermatol. 1989;(3):413\u20136.","DOI":"10.1111\/1523-1747.ep12280303"},{"issue":"440","key":"1646_CR3","doi-asserted-by":"publisher","first-page":"eaar5894","DOI":"10.1126\/scitranslmed.aar5894","volume":"10","author":"A de Masson","year":"2018","unstructured":"de Masson A, O\u2019Malley JT, Elco CP, et al. High-throughput sequencing of the T cell receptor \u03b2 gene identifies aggressive early-stage mycosis fungoides. Sci Transl Med. 2018;10(440):eaar5894. https:\/\/doi.org\/10.1126\/scitranslmed.aar5894.","journal-title":"Sci Transl Med"},{"issue":"10","key":"1646_CR4","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1158\/1078-0432.CCR-18-3309","volume":"25","author":"N Borcherding","year":"2019","unstructured":"Borcherding N, Voigt AP, Liu V, et al. Single-cell profiling of cutaneous T-Cell lymphoma reveals underlying Heterogeneity Associated with Disease Progression. Clin Cancer Res. 2019;25(10):2996\u20133005. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3309.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1646_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.5021\/ad.2021.33.6.487","volume":"33","author":"Z Liu","year":"2021","unstructured":"Liu Z, Wu X, Hwang ST, Liu J. The role of Tumor Microenvironment in Mycosis Fungoides and S\u00e9zary Syndrome. Ann Dermatol. 2021;33(6):487\u201396. https:\/\/doi.org\/10.5021\/ad.2021.33.6.487.","journal-title":"Ann Dermatol"},{"issue":"16","key":"1646_CR6","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921\u20135. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081.","journal-title":"Curr Biol"},{"issue":"10","key":"1646_CR7","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.3390\/cells10102780","volume":"10","author":"A Pileri","year":"2021","unstructured":"Pileri A, Guglielmo A, Grandi V, et al. The Microenvironment\u2019s role in Mycosis Fungoides and S\u00e9zary Syndrome: from progression to therapeutic implications. Cells. 2021;10(10):2780. https:\/\/doi.org\/10.3390\/cells10102780.","journal-title":"Cells"},{"issue":"16","key":"1646_CR8","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1158\/1078-0432.CCR-06-0532","volume":"12","author":"S Hahtola","year":"2006","unstructured":"Hahtola S, Tuomela S, Elo L, et al. Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clin Cancer Res. 2006;12(16):4812\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0532.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"1646_CR9","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","volume":"19","author":"E Guenova","year":"2013","unstructured":"Guenova E, Watanabe R, Teague JE, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res. 2013;19(14):3755\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3488.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1646_CR10","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","volume":"94","author":"AH Rook","year":"1999","unstructured":"Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood. 1999;94(3):902\u20138.","journal-title":"Blood"},{"issue":"4","key":"1646_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.det.2015.05.008","volume":"33","author":"N Spaccarelli","year":"2015","unstructured":"Spaccarelli N, Rook AH. The Use of interferons in the treatment of cutaneous T-Cell lymphoma. Dermatol Clin. 2015;33(4):731\u201345. https:\/\/doi.org\/10.1016\/j.det.2015.05.008.","journal-title":"Dermatol Clin"},{"key":"1646_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jdcr.2020.12.010","volume":"8","author":"K Russomanno","year":"2020","unstructured":"Russomanno K, Carver DeKlotz CM. Acceleration of cutaneous T-cell lymphoma following dupilumab administration. JAAD Case Rep. 2020;8:83\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.010.","journal-title":"JAAD Case Rep"},{"issue":"3","key":"1646_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/leu.2011.237","volume":"26","author":"T Krejsgaard","year":"2012","unstructured":"Krejsgaard T, Odum N, Geisler C, et al. Regulatory T cells and immunodeficiency in mycosis fungoides and S\u00e9zary syndrome. Leukemia. 2012;26(3):424\u201332. https:\/\/doi.org\/10.1038\/leu.2011.237.","journal-title":"Leukemia"},{"issue":"3","key":"1646_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00262-017-2090-z","volume":"67","author":"LJ Geskin","year":"2018","unstructured":"Geskin LJ, Akilov OE, Kwon S, et al. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and S\u00e9zary syndrome. Cancer Immunol Immunother. 2018;67(3):423\u201334. https:\/\/doi.org\/10.1007\/s00262-017-2090-z.","journal-title":"Cancer Immunol Immunother"},{"issue":"23","key":"1646_CR15","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1200\/JCO.2001.19.23.4322","volume":"19","author":"MH Vermeer","year":"2001","unstructured":"Vermeer MH, van Doorn R, Dukers D, et al. CD8\u2009+\u2009T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol. 2001;19(23):4322\u20139. https:\/\/doi.org\/10.1200\/JCO.2001.19.23.4322.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1646_CR16","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/2326-6066.CIR-17-0270","volume":"6","author":"C Querfeld","year":"2018","unstructured":"Querfeld C, Leung S, Myskowski PL, et al. Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted Immune Checkpoint Profile. Cancer Immunol Res. 2018;6(8):900\u20139. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0270.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"1646_CR17","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/jdv.13651","volume":"30","author":"LY McGirt","year":"2016","unstructured":"McGirt LY, Degesys CA, Johnson VE, et al. TOX expression and role in CTCL. J Eur Acad Dermatol Venereol. 2016;30(9):1497\u2013502. https:\/\/doi.org\/10.1111\/jdv.13651.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1646_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/bjd.13832","volume":"173","author":"CD Klemke","year":"2015","unstructured":"Klemke CD, Booken N, Weiss C, et al. Histopathological and immunophenotypical criteria for the diagnosis of S\u00e9zary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) cutaneous lymphoma Task Force Study of 97 cases. Br J Dermatol. 2015;173(1):93\u2013105. https:\/\/doi.org\/10.1111\/bjd.13832.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1646_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","volume":"116","author":"JJ Campbell","year":"2010","unstructured":"Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767\u201371. https:\/\/doi.org\/10.1182\/blood-2009-11-251926.","journal-title":"Blood"},{"issue":"13","key":"1646_CR20","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3390\/ijms22136995","volume":"22","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier AJ, Elsawa SF. Macrophage polarization States in the Tumor Microenvironment. Int J Mol Sci. 2021;22(13):6995. https:\/\/doi.org\/10.3390\/ijms22136995.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1646_CR21","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/jid.2014.206","volume":"134","author":"X Wu","year":"2014","unstructured":"Wu X, Schulte BC, Zhou Y, et al. Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol. 2014;134(11):2814\u201322. https:\/\/doi.org\/10.1038\/jid.2014.206.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"1646_CR22","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.3390\/cancers14112749","volume":"14","author":"YR Li","year":"2022","unstructured":"Li YR, Brown J, Yu Y, et al. Targeting Immunosuppressive Tumor-Associated macrophages using innate T cells for enhanced Antitumor Reactivity. Cancers (Basel). 2022;14(11):2749. https:\/\/doi.org\/10.3390\/cancers14112749.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1646_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jdermsci.2012.07.007","volume":"68","author":"M Sugaya","year":"2012","unstructured":"Sugaya M, Miyagaki T, Ohmatsu H, et al. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci. 2012;68(1):45\u201351. https:\/\/doi.org\/10.1016\/j.jdermsci.2012.07.007.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"1646_CR24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1186\/s12885-024-12472-7","volume":"24","author":"S Liu","year":"2024","unstructured":"Liu S, Zhang S, Dong H, et al. CD63\u2009+\u2009tumor-associated macrophages drive the progression of hepatocellular carcinoma through the induction of epithelial-mesenchymal transition and lipid reprogramming. BMC Cancer. 2024;24(1):698. https:\/\/doi.org\/10.1186\/s12885-024-12472-7.","journal-title":"BMC Cancer"},{"issue":"5","key":"1646_CR25","first-page":"3037","volume":"14","author":"S Huang","year":"2022","unstructured":"Huang S, Liao M, Chen S, Zhang P, et al. Immune signatures of CD4 and CD68 predicts disease progression in cutaneous T cell lymphoma. Am J Transl Res. 2022;14(5):3037\u201351.","journal-title":"Am J Transl Res"},{"issue":"3","key":"1646_CR26","doi-asserted-by":"publisher","first-page":"adv00413","DOI":"10.2340\/00015555-3775","volume":"101","author":"PR Nielsen","year":"2021","unstructured":"Nielsen PR, Eriksen JO, S\u00f8rensen MD, et al. Role of B-cells in Mycosis Fungoides. Acta Derm Venereol. 2021;101(3):adv00413. https:\/\/doi.org\/10.2340\/00015555-3775.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1646_CR27","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1684\/ejd.2016.2847","volume":"26","author":"A Iliadis","year":"2016","unstructured":"Iliadis A, Koletsa T, Patsatsi A, Georgiou E, et al. The cellular microenvironment and neoplastic population in mycosis fungoides skin lesions: a clinicopathological correlation. Eur J Dermatol. 2016;26(6):566\u201371. https:\/\/doi.org\/10.1684\/ejd.2016.2847.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"1646_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1684\/ejd.2018.3319","volume":"28","author":"T Akatsuka","year":"2018","unstructured":"Akatsuka T, Miyagaki T, Nakajima R, et al. Decreased IL-10-producing regulatory B cells in patients with advanced mycosis fungoides. Eur J Dermatol. 2018;28(3):314\u20139. https:\/\/doi.org\/10.1684\/ejd.2018.3319.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"1646_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi G, Tuveson DA. Diversity and Biology of Cancer-Associated fibroblasts. Physiol Rev. 2021;101(1):147\u201376. https:\/\/doi.org\/10.1152\/physrev.00048.2019.","journal-title":"Physiol Rev"},{"issue":"14","key":"1646_CR30","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","volume":"76","author":"X Yang","year":"2016","unstructured":"Yang X, Lin Y, Shi Y, et al. FAP promotes immunosuppression by Cancer-Associated fibroblasts in the Tumor Microenvironment via STAT3-CCL2 signaling. Cancer Res. 2016;76(14):4124\u201335. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2973.","journal-title":"Cancer Res"},{"issue":"3","key":"1646_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jid.2020.06.034","volume":"141","author":"A Aronovich","year":"2021","unstructured":"Aronovich A, Moyal L, Gorovitz B, et al. Cancer-Associated fibroblasts in Mycosis Fungoides promote Tumor Cell Migration and Drug Resistance through CXCL12\/CXCR4. J Invest Dermatol. 2021;141(3):619\u2013e6272. https:\/\/doi.org\/10.1016\/j.jid.2020.06.034.","journal-title":"J Invest Dermatol"},{"key":"1646_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2019.07.004","volume":"348","author":"S Balan","year":"2019","unstructured":"Balan S, Saxena M, Bhardwaj N. Dendritic cell subsets and locations. Int Rev Cell Mol Biol. 2019;348:1\u201368. https:\/\/doi.org\/10.1016\/bs.ircmb.2019.07.004.","journal-title":"Int Rev Cell Mol Biol"},{"issue":"3","key":"1646_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2340\/00015555-1220","volume":"92","author":"P Schwingshackl","year":"2012","unstructured":"Schwingshackl P, Obermoser G, Nguyen VA, et al. Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma: mycosis fungoides and S\u00e9zary syndrome. Acta Derm Venereol. 2012;92(3):269\u201375. https:\/\/doi.org\/10.2340\/00015555-1220.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1646_CR34","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jaad.2009.06.082","volume":"62","author":"C Schlapbach","year":"2010","unstructured":"Schlapbach C, Ochsenbein A, Kaelin U, et al. High numbers of DC-SIGN\u2009+\u2009dendritic cells in lesional skin of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2010;62(6):995\u20131004. https:\/\/doi.org\/10.1016\/j.jaad.2009.06.082.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1646_CR35","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1182\/blood.V99.8.2929","volume":"99","author":"CL Berger","year":"2002","unstructured":"Berger CL, Hanlon D, Kanada D, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood. 2002;99(8):2929\u201339.","journal-title":"Blood"},{"issue":"22","key":"1646_CR36","doi-asserted-by":"publisher","first-page":"8790","DOI":"10.3390\/ijms21228790","volume":"21","author":"M Piipponen","year":"2020","unstructured":"Piipponen M, Li D, Land\u00e9n NX. The Immune functions of keratinocytes in skin Wound Healing. Int J Mol Sci. 2020;21(22):8790. https:\/\/doi.org\/10.3390\/ijms21228790.","journal-title":"Int J Mol Sci"},{"key":"1646_CR37","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3389\/fcell.2020.00851","volume":"8","author":"V Stolearenco","year":"2020","unstructured":"Stolearenco V, Namini MRJ, Hasselager SS, et al. Cellular interactions and inflammation in the pathogenesis of cutaneous T-Cell lymphoma. Front Cell Dev Biol. 2020;8:851. https:\/\/doi.org\/10.3389\/fcell.2020.00851.","journal-title":"Front Cell Dev Biol"},{"issue":"21","key":"1646_CR38","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1158\/0008-5472.CAN-16-0992","volume":"76","author":"N Takahashi","year":"2016","unstructured":"Takahashi N, Sugaya M, Suga H, et al. Thymic stromal chemokine TSLP acts through Th2 Cytokine production to induce cutaneous T-cell lymphoma. Cancer Res. 2016;76(21):6241\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0992.","journal-title":"Cancer Res"},{"issue":"6","key":"1646_CR39","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/bjd.16237","volume":"178","author":"R Nakajima","year":"2018","unstructured":"Nakajima R, Miyagaki T, Hirakawa M, et al. Interleukin-25 is involved in cutaneous T-cell lymphoma progression by establishing a T helper 2-dominant microenvironment. Br J Dermatol. 2018;178(6):1373\u201382. https:\/\/doi.org\/10.1111\/bjd.16237.","journal-title":"Br J Dermatol"},{"issue":"18","key":"1646_CR40","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","volume":"125","author":"LJ Geskin","year":"2015","unstructured":"Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015;125(18):2798\u2013805. https:\/\/doi.org\/10.1182\/blood-2014-07-590398.","journal-title":"Blood"},{"issue":"24","key":"1646_CR41","doi-asserted-by":"publisher","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-11-1192","volume":"17","author":"T Miyagaki","year":"2011","unstructured":"Miyagaki T, Sugaya M, Suga H, et al. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res. 2011;17(24):7529\u201338. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1192.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"1646_CR42","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-14-0077","volume":"20","author":"H Suga","year":"2014","unstructured":"Suga H, Sugaya M, Miyagaki T, et al. Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous T-cell lymphoma. Clin Cancer Res. 2014;20(16):4339\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0077.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1646_CR43","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1182\/blood.2022016690","volume":"141","author":"M Gluud","year":"2023","unstructured":"Gluud M, Pallesen EMH, Buus TB, et al. Malignant T cells induce skin barrier defects through cytokine-mediated JAK\/STAT signaling in cutaneous T-cell lymphoma. Blood. 2023;141(2):180\u201393. https:\/\/doi.org\/10.1182\/blood.2022016690.","journal-title":"Blood"},{"issue":"1","key":"1646_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/BF02893406","volume":"10","author":"G Mazur","year":"2004","unstructured":"Mazur G, Wo\u017aniak Z, Wr\u00f3bel T, et al. Increased angiogenesis in cutaneous T-cell lymphomas. Pathol Oncol Res. 2004;10(1):34\u20136. https:\/\/doi.org\/10.1007\/BF02893406.","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"1646_CR45","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjd.13054","volume":"171","author":"RN Daggett","year":"2014","unstructured":"Daggett RN, Kurata M, Abe S, et al. Expression dynamics of CXCL12 and CXCR4 during the progression of mycosis fungoides. Br J Dermatol. 2014;171(4):722\u201331. https:\/\/doi.org\/10.1111\/bjd.13054.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1646_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2340\/00015555-1633","volume":"94","author":"M Kawaguchi","year":"2014","unstructured":"Kawaguchi M, Sugaya M, Suga H, et al. Serum levels of angiopoietin-2, but not angiopoietin-1, are elevated in patients with erythrodermic cutaneous T-cell lymphoma. Acta Derm Venereol. 2014;94(1):9\u201313. https:\/\/doi.org\/10.2340\/00015555-1633.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1646_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3109\/10428194.2010.517877","volume":"52","author":"MB Karpova","year":"2011","unstructured":"Karpova MB, Fujii K, Jenni D, et al. Evaluation of lymphangiogenic markers in S\u00e9zary syndrome. Leuk Lymphoma. 2011;52(3):491\u2013501. https:\/\/doi.org\/10.3109\/10428194.2010.517877.","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"1646_CR48","doi-asserted-by":"publisher","first-page":"15235","DOI":"10.18632\/oncotarget.3837","volume":"6","author":"B Lauenborg","year":"2015","unstructured":"Lauenborg B, Christensen L, Ralfkiaer U, et al. Malignant T cells express lymphotoxin \u03b1 and drive endothelial activation in cutaneous T cell lymphoma. Oncotarget. 2015;6(17):15235\u201349. https:\/\/doi.org\/10.18632\/oncotarget.3837.","journal-title":"Oncotarget"},{"issue":"1","key":"1646_CR49","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-019-0797-3","volume":"12","author":"M Lv","year":"2019","unstructured":"Lv M, Wang K, Huang XJ. Myeloid-derived suppressor cells in hematological malignancies: friends or foes. J Hematol Oncol. 2019;12(1):105. https:\/\/doi.org\/10.1186\/s13045-019-0797-3.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1646_CR50","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s12094-019-02231-7","volume":"22","author":"KV Argyropoulos","year":"2020","unstructured":"Argyropoulos KV, Pulitzer M, Perez S, et al. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides. Clin Transl Oncol. 2020;22(7):1059\u201366. https:\/\/doi.org\/10.1007\/s12094-019-02231-7.","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"1646_CR51","doi-asserted-by":"publisher","first-page":"e96219","DOI":"10.1172\/jci.insight.96219","volume":"3","author":"M Felices","year":"2018","unstructured":"Felices M, Lenvik AJ, McElmurry R, et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight. 2018;3(3):e96219. https:\/\/doi.org\/10.1172\/jci.insight.96219.","journal-title":"JCI Insight"},{"issue":"4","key":"1646_CR52","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1158\/2159-8290.CD-15-0732","volume":"6","author":"D Gotthardt","year":"2016","unstructured":"Gotthardt D, Putz EM, Grundschober E, et al. STAT5 is a Key Regulator in NK cells and acts as a molecular switch from Tumor Surveillance to Tumor Promotion. Cancer Discov. 2016;6(4):414\u201329. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0732.","journal-title":"Cancer Discov"},{"key":"1646_CR53","doi-asserted-by":"publisher","first-page":"1168684","DOI":"10.3389\/fimmu.2023.1168684","volume":"14","author":"A Scheffschick","year":"2023","unstructured":"Scheffschick A, Nenonen J, Xiang M, et al. Skin infiltrating NK cells in cutaneous T-cell lymphoma are increased in number and display phenotypic alterations partially driven by the tumor. Front Immunol. 2023;14:1168684. https:\/\/doi.org\/10.3389\/fimmu.2023.1168684.","journal-title":"Front Immunol"},{"key":"1646_CR54","doi-asserted-by":"publisher","unstructured":"Wechsler ME, Munitz A, Ackerman SJ et al. Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo Clin Proc. 2021;96(10):2694\u20132707. https:\/\/doi.org\/10.1016\/j.mayocp.2021.04.025","DOI":"10.1016\/j.mayocp.2021.04.025"},{"issue":"6","key":"1646_CR55","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/DAD.0b013e31823d921b","volume":"34","author":"SR Dalton","year":"2012","unstructured":"Dalton SR, Chandler WM, Abuzeid M, et al. Eosinophils in mycosis fungoides: an uncommon finding in the patch and plaque stages. Am J Dermatopathol. 2012;34(6):586\u201391. https:\/\/doi.org\/10.1097\/DAD.0b013e31823d921b.","journal-title":"Am J Dermatopathol"},{"issue":"9","key":"1646_CR56","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/archderm.140.9.1057","volume":"140","author":"E Tancr\u00e8de-Bohin","year":"2004","unstructured":"Tancr\u00e8de-Bohin E, Ionescu MA, de La Salmoni\u00e8re P, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol. 2004;140(9):1057\u201361. https:\/\/doi.org\/10.1001\/archderm.140.9.1057.","journal-title":"Arch Dermatol"},{"issue":"10","key":"1646_CR57","first-page":"5277","volume":"34","author":"S Fredholm","year":"2014","unstructured":"Fredholm S, Gjerdrum LM, Willerslev-Olsen A, et al. STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides. Anticancer Res. 2014;34(10):5277\u201386.","journal-title":"Anticancer Res"},{"issue":"4","key":"1646_CR58","first-page":"749","volume":"6","author":"T Terada","year":"2013","unstructured":"Terada T. Mycosis fungoides in plaque stage with pronounced eosinophilic infiltration, folliculotropism, and concomitant invasive squamous cell carcinoma. Int J Clin Exp Pathol. 2013;6(4):749\u201356.","journal-title":"Int J Clin Exp Pathol"},{"issue":"4","key":"1646_CR59","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1034\/j.1600-0560.2001.028004174.x","volume":"28","author":"J Guitart","year":"2001","unstructured":"Guitart J, Kennedy J, Ronan S, et al. Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting. J Cutan Pathol. 2001;28(4):174\u201383. https:\/\/doi.org\/10.1034\/j.1600-0560.2001.028004174.x.","journal-title":"J Cutan Pathol"},{"key":"1646_CR60","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fphys.2018.00113","volume":"9","author":"C Rosales","year":"2018","unstructured":"Rosales C, Neutrophil. A cell with many roles in inflammation or several cell types? Front Physiol. 2018;9:113. https:\/\/doi.org\/10.3389\/fphys.2018.00113.","journal-title":"Front Physiol"},{"issue":"23","key":"1646_CR61","doi-asserted-by":"publisher","first-page":"8243","DOI":"10.1158\/1078-0432.CCR-05-1434","volume":"11","author":"DS Goddard","year":"2005","unstructured":"Goddard DS, Yamanaka K, Kupper TS, Jones DA. Activation of neutrophils in cutaneous T-cell lymphoma. Clin Cancer Res. 2005;11(23):8243\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1434.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1646_CR62","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1172\/JCI118625","volume":"97","author":"DD Taub","year":"1996","unstructured":"Taub DD, Anver M, Oppenheim JJ, et al. T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest. 1996;97(8):1931\u201341. https:\/\/doi.org\/10.1172\/JCI118625.","journal-title":"J Clin Invest"},{"issue":"3","key":"1646_CR63","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1365-2133.2011.10647.x","volume":"166","author":"L Fontao","year":"2012","unstructured":"Fontao L, Brembilla NC, Masouy\u00e9 I, et al. Interleukin-17 expression in neutrophils and Th17 cells in cutaneous T-cell lymphoma associated with neutrophilic infiltrate of the skin. Br J Dermatol. 2012;166(3):687\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10647.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1646_CR64","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/jid.2011.27","volume":"131","author":"T Krejsgaard","year":"2011","unstructured":"Krejsgaard T, Ralfkiaer U, Clasen-Linde E, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3\/Stat3 signaling pathway. J Invest Dermatol. 2011;131(6):1331\u20138. https:\/\/doi.org\/10.1038\/jid.2011.27.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"1646_CR65","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.3390\/diagnostics13111979","volume":"13","author":"C Di Raimondo","year":"2023","unstructured":"Di Raimondo C, Lombardo P, Tesei C, et al. Role of Neutrophil-to-lymphocyte ratio (NLR) in patients with Mycosis Fungoides. Diagnostics (Basel). 2023;13(11):1979. https:\/\/doi.org\/10.3390\/diagnostics13111979.","journal-title":"Diagnostics (Basel)"},{"issue":"11","key":"1646_CR66","doi-asserted-by":"publisher","first-page":"e0163661","DOI":"10.1371\/journal.pone.0163661","volume":"11","author":"J Eder","year":"2016","unstructured":"Eder J, Rogojanu R, Jerney W, et al. Mast cells are abundant in primary cutaneous T-Cell lymphomas: results from a computer-aided quantitative Immunohistological Study. PLoS ONE. 2016;11(11):e0163661. https:\/\/doi.org\/10.1371\/journal.pone.0163661.","journal-title":"PLoS ONE"},{"issue":"10","key":"1646_CR67","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood-2012-03-415638","volume":"120","author":"A Rabenhorst","year":"2012","unstructured":"Rabenhorst A, Schlaak M, Heukamp LC, et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood. 2012;120(10):2042\u201354. https:\/\/doi.org\/10.1182\/blood-2012-03-415638.","journal-title":"Blood"},{"issue":"3","key":"1646_CR68","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2165\/00128071-200203030-00006","volume":"3","author":"N Apisarnthanarax","year":"2002","unstructured":"Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol. 2002;3(3):193\u2013215. https:\/\/doi.org\/10.2165\/00128071-200203030-00006.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1646_CR69","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/cancers11101420","volume":"11","author":"M Bobrowicz","year":"2019","unstructured":"Bobrowicz M, Zagozdzon R, Domagala J, et al. Monoclonal antibodies in Dermatooncology-State of the art and future perspectives. Cancers (Basel). 2019;11(10):1420. https:\/\/doi.org\/10.3390\/cancers11101420.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1646_CR70","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00011-017-1032-8","volume":"66","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Su H, Shen X, et al. The immunological function of CD52 and its targeting in organ transplantation. Inflamm Res. 2017;66(7):571\u20138. https:\/\/doi.org\/10.1007\/s00011-017-1032-8.","journal-title":"Inflamm Res"},{"issue":"3","key":"1646_CR71","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/bjd.12690","volume":"170","author":"A de Masson","year":"2014","unstructured":"de Masson A, Guitera P, Brice P, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol. 2014;170(3):720\u20134. https:\/\/doi.org\/10.1111\/bjd.12690.","journal-title":"Br J Dermatol"},{"issue":"117","key":"1646_CR72","doi-asserted-by":"publisher","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","volume":"4","author":"RA Clark","year":"2012","unstructured":"Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med. 2012;4(117):117ra7. https:\/\/doi.org\/10.1126\/scitranslmed.3003008.","journal-title":"Sci Transl Med"},{"key":"1646_CR73","unstructured":"Northwestern University. Phase II Trial Of Campath-1H In Patients With Relapsed\/Refractory Advanced Mycosis Fungoides or Sezary Syndrome. https:\/\/clinicaltrials.gov\/study\/NCT00057967 (2019)."},{"issue":"4","key":"1646_CR74","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/mabs.20230","volume":"4","author":"NW van de Donk","year":"2012","unstructured":"van de Donk NW, Dhimolea E, Brentuximab vedotin. MAbs. 2012;4(4):458\u201365. https:\/\/doi.org\/10.4161\/mabs.20230.","journal-title":"MAbs"},{"issue":"5","key":"1646_CR75","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","volume":"24","author":"NC Richardson","year":"2019","unstructured":"Richardson NC, Kasamon YL, Chen H, et al. FDA approval Summary: Brentuximab Vedotin in First-Line treatment of Peripheral T-Cell Lymphoma. Oncologist. 2019;24(5):e180\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2019-0098.","journal-title":"Oncologist"},{"issue":"21","key":"1646_CR76","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.3390\/cancers13215542","volume":"13","author":"O Yoshie","year":"2021","unstructured":"Yoshie O. CCR4 as a therapeutic target for Cancer Immunotherapy. Cancers (Basel). 2021;13(21):5542. https:\/\/doi.org\/10.3390\/cancers13215542.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1646_CR77","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/eji.202049043","volume":"51","author":"JP Nicolay","year":"2021","unstructured":"Nicolay JP, Albrecht JD, Alberti-Violetti S, Berti E. CCR4 in cutaneous T-cell lymphoma: therapeutic targeting of a pathogenic driver. Eur J Immunol. 2021;51(7):1660\u201371. https:\/\/doi.org\/10.1002\/eji.202049043.","journal-title":"Eur J Immunol"},{"issue":"8","key":"1646_CR78","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00262-008-0632-0","volume":"58","author":"A Ito","year":"2009","unstructured":"Ito A, Ishida T, Yano H, et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD\/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother. 2009;58(8):1195\u2013206. https:\/\/doi.org\/10.1007\/s00262-008-0632-0.","journal-title":"Cancer Immunol Immunother"},{"key":"1646_CR79","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3389\/fimmu.2019.01179","volume":"10","author":"D Pende","year":"2019","unstructured":"Pende D, Falco M, Vitale M, et al. Killer Ig-Like receptors (KIRs): their role in NK Cell Modulation and Developments leading to their Clinical Exploitation. Front Immunol. 2019;10:1179. https:\/\/doi.org\/10.3389\/fimmu.2019.01179.","journal-title":"Front Immunol"},{"issue":"14","key":"1646_CR80","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1158\/1078-0432.CCR-16-3185","volume":"23","author":"C Hurabielle","year":"2017","unstructured":"Hurabielle C, Thonnart N, Ram-Wolff C, et al. Usefulness of KIR3DL2 to diagnose, Follow-Up, and manage the treatment of patients with S\u00e9zary Syndrome. Clin Cancer Res. 2017;23(14):3619\u201327. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3185.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1646_CR81","doi-asserted-by":"publisher","first-page":"e1022306","DOI":"10.1080\/2162402X.2015.1022306","volume":"4","author":"H Sicard","year":"2015","unstructured":"Sicard H, Bonnafous C, Morel A, et al. A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. Oncoimmunology. 2015;4(9):e1022306. https:\/\/doi.org\/10.1080\/2162402X.2015.1022306.","journal-title":"Oncoimmunology"},{"issue":"6145","key":"1646_CR82","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/330256a0","volume":"330","author":"C Doyle","year":"1987","unstructured":"Doyle C, Strominger JL. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature. 1987;330(6145):256\u20139. https:\/\/doi.org\/10.1038\/330256a0.","journal-title":"Nature"},{"issue":"12","key":"1646_CR83","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1517\/14712590802528696","volume":"8","author":"DS Mestel","year":"2008","unstructured":"Mestel DS, Beyer M, M\u00f6bs M, et al. Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and S\u00e9zary syndrome. Expert Opin Biol Ther. 2008;8(12):1929\u201339. https:\/\/doi.org\/10.1517\/14712590802528696.","journal-title":"Expert Opin Biol Ther"},{"key":"1646_CR84","doi-asserted-by":"publisher","unstructured":"Zang X. 2018 Nobel Prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade - A personal account. Genes Dis. 2018;5(4):302\u2013303. https:\/\/doi.org\/10.1016\/j.gendis.2018.10.003","DOI":"10.1016\/j.gendis.2018.10.003"},{"issue":"3","key":"1646_CR85","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727\u201342.","journal-title":"Am J Cancer Res"},{"issue":"12","key":"1646_CR86","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1001\/archdermatol.2010.200","volume":"146","author":"S Samimi","year":"2010","unstructured":"Samimi S, Benoit B, Evans K, et al. Increased programmed death-1 expression on CD4\u2009+\u2009T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol. 2010;146(12):1382\u20138. https:\/\/doi.org\/10.1001\/archdermatol.2010.200.","journal-title":"Arch Dermatol"},{"issue":"2","key":"1646_CR87","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/bjd.21063","volume":"187","author":"C Di Raimondo","year":"2022","unstructured":"Di Raimondo C, Rubio-Gonzalez B, Palmer J, et al. Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and S\u00e9zary syndrome: association with disease stage and clinical outcome. Br J Dermatol. 2022;187(2):234\u201343. https:\/\/doi.org\/10.1111\/bjd.21063.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1646_CR88","doi-asserted-by":"publisher","first-page":"1738797","DOI":"10.1080\/2162402X.2020.1738797","volume":"9","author":"I Saulite","year":"2020","unstructured":"Saulite I, Ignatova D, Chang YT, et al. Blockade of programmed cell death protein 1 (PD-1) in S\u00e9zary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. Oncoimmunology. 2020;9(1):1738797. https:\/\/doi.org\/10.1080\/2162402X.2020.1738797.","journal-title":"Oncoimmunology"},{"issue":"4","key":"1646_CR89","doi-asserted-by":"publisher","first-page":"e164793","DOI":"10.1172\/jci.insight.164793","volume":"8","author":"Y Gao","year":"2023","unstructured":"Gao Y, Hu S, Li R, et al. Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment. JCI Insight. 2023;8(4):e164793. https:\/\/doi.org\/10.1172\/jci.insight.164793.","journal-title":"JCI Insight"},{"issue":"1","key":"1646_CR90","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/sj.jid.5700029","volume":"126","author":"HK Wong","year":"2006","unstructured":"Wong HK, Wilson AJ, Gibson HM, et al. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides -- cutaneous T cell lymphoma. J Invest Dermatol. 2006;126(1):212\u20139. https:\/\/doi.org\/10.1038\/sj.jid.5700029.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"1646_CR91","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1080\/10428194.2018.1564827","volume":"60","author":"F Anzengruber","year":"2019","unstructured":"Anzengruber F, Ignatova D, Schlaepfer T, et al. Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in S\u00e9zary syndrome. Leuk Lymphoma. 2019;60(8):1899\u2013907. https:\/\/doi.org\/10.1080\/10428194.2018.1564827.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1646_CR92","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/jid.2012.265","volume":"133","author":"HM Gibson","year":"2013","unstructured":"Gibson HM, Mishra A, Chan DV, et al. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for S\u00e9zary syndrome. J Invest Dermatol. 2013;133(1):249\u201357. https:\/\/doi.org\/10.1038\/jid.2012.265.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1646_CR93","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdcr.2015.02.009","volume":"1","author":"G Bar-Sela","year":"2015","unstructured":"Bar-Sela G, Bergman R. Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma. JAAD Case Rep. 2015;1(2):99\u2013100. https:\/\/doi.org\/10.1016\/j.jdcr.2015.02.009.","journal-title":"JAAD Case Rep"},{"issue":"2","key":"1646_CR94","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/mgg3.121","volume":"3","author":"A Sekulic","year":"2015","unstructured":"Sekulic A, Liang WS, Tembe W, et al. Personalized treatment of S\u00e9zary syndrome by targeting a novel CTLA4:CD28 fusion. Mol Genet Genomic Med. 2015;3(2):130\u20136. https:\/\/doi.org\/10.1002\/mgg3.121.","journal-title":"Mol Genet Genomic Med"},{"issue":"8","key":"1646_CR95","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jid.2023.02.017","volume":"143","author":"Z Han","year":"2023","unstructured":"Han Z, Wu X, Qin H, et al. Blockade of the Immune Checkpoint CD47 by TTI-621 potentiates the response to Anti-PD-L1 in cutaneous T-Cell lymphoma. J Invest Dermatol. 2023;143(8):1569\u2013e15785. https:\/\/doi.org\/10.1016\/j.jid.2023.02.017.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"1646_CR96","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1016\/S2352-3026(21)00271-4","volume":"8","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Thompson JA, Taylor MH, et al. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or S\u00e9zary syndrome: a multicentre, phase 1 study. Lancet Haematol. 2021;8(11):e808\u201317. https:\/\/doi.org\/10.1016\/S2352-3026(21)00271-4.","journal-title":"Lancet Haematol"},{"issue":"3","key":"1646_CR97","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41375-019-0622-6","volume":"34","author":"H Kamijo","year":"2020","unstructured":"Kamijo H, Miyagaki T, Takahashi-Shishido N, et al. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47. Leukemia. 2020;34(3):845\u201356. https:\/\/doi.org\/10.1038\/s41375-019-0622-6.","journal-title":"Leukemia"},{"issue":"1","key":"1646_CR98","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF02175100","volume":"3","author":"OW Press","year":"1991","unstructured":"Press OW, Immunotoxins. Biotherapy. 1991;3(1):65\u201376. https:\/\/doi.org\/10.1007\/BF02175100.","journal-title":"Biotherapy"},{"key":"1646_CR99","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/cmar.s5009","volume":"2","author":"F Lansigan","year":"2010","unstructured":"Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag Res. 2010;2:53\u20139. https:\/\/doi.org\/10.2147\/cmar.s5009.","journal-title":"Cancer Manag Res"},{"issue":"7","key":"1646_CR100","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/2211-5463.13625","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang Z, Ma J, Zhang H, et al. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023;13(7):1309\u201319. https:\/\/doi.org\/10.1002\/2211-5463.13625.","journal-title":"FEBS Open Bio"},{"issue":"6","key":"1646_CR101","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3324\/haematol.2015.123711","volume":"100","author":"AE Frankel","year":"2015","unstructured":"Frankel AE, Woo JH, Ahn C, et al. Resimmune, an anti-CD3\u03b5 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 2015;100(6):794\u2013800. https:\/\/doi.org\/10.3324\/haematol.2015.123711.","journal-title":"Haematologica"},{"issue":"6","key":"1646_CR102","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2217\/imt.09.70","volume":"1","author":"S Adams","year":"2009","unstructured":"Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009;1(6):949\u201364. https:\/\/doi.org\/10.2217\/imt.09.70.","journal-title":"Immunotherapy"},{"issue":"2","key":"1646_CR103","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/ced.13008","volume":"42","author":"AM El Tawdy","year":"2017","unstructured":"El Tawdy AM, Amin IM, Abdel Hay RM, et al. Toll-like receptor (TLR)7 expression in mycosis fungoides and psoriasis: a case-control study. Clin Exp Dermatol. 2017;42(2):172\u20137. https:\/\/doi.org\/10.1111\/ced.13008.","journal-title":"Clin Exp Dermatol"},{"key":"1646_CR104","doi-asserted-by":"publisher","unstructured":"Rook AH, Gelfand JM, Wysocka M et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126(12):1452-61. https:\/\/doi.org\/10.1182\/blood-2015-02-630335. Erratum in: Blood. 2015;126(25):2765. Gelfand, Joel C [corrected to Gelfand, Joel M].","DOI":"10.1182\/blood-2015-02-630335"},{"issue":"2","key":"1646_CR105","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1182\/blood-2011-05-355222","volume":"119","author":"YH Kim","year":"2012","unstructured":"Kim YH, Gratzinger D, Harrison C, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1\/2 study. Blood. 2012;119(2):355\u201363. https:\/\/doi.org\/10.1182\/blood-2011-05-355222.","journal-title":"Blood"},{"key":"1646_CR106","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","volume":"10","author":"Z Zou","year":"2020","unstructured":"Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020;10:31. https:\/\/doi.org\/10.1186\/s13578-020-00396-1.","journal-title":"Cell Biosci"},{"issue":"12","key":"1646_CR107","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.3390\/ijms22126567","volume":"22","author":"W Chen","year":"2021","unstructured":"Chen W, Zhang Z, Zhang S, et al. MUC1: structure, function, and Clinic Application in epithelial cancers. Int J Mol Sci. 2021;22(12):6567. https:\/\/doi.org\/10.3390\/ijms22126567.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1646_CR108","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2015-02-628149","volume":"126","author":"S Jain","year":"2015","unstructured":"Jain S, Stroopinsky D, Yin L, et al. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2015;126(3):354\u201362. https:\/\/doi.org\/10.1182\/blood-2015-02-628149.","journal-title":"Blood"},{"issue":"10","key":"1646_CR109","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1158\/1535-7163.MCT-17-0060","volume":"16","author":"S Jain","year":"2017","unstructured":"Jain S, Washington A, Leaf RK, et al. Decitabine Priming enhances mucin 1 inhibition mediated disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Mol Cancer Ther. 2017;16(10):2304\u201314. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0060.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1646_CR110","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","volume":"1","author":"S Ropero","year":"2007","unstructured":"Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1(1):19\u201325. https:\/\/doi.org\/10.1016\/j.molonc.2007.01.001.","journal-title":"Mol Oncol"},{"issue":"9","key":"1646_CR111","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1358\/dot.2007.43.9.1112980","volume":"43","author":"M Duvic","year":"2007","unstructured":"Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc). 2007;43(9):585\u201399. https:\/\/doi.org\/10.1358\/dot.2007.43.9.1112980.","journal-title":"Drugs Today (Barc)"},{"key":"1646_CR112","doi-asserted-by":"publisher","unstructured":"Grant C, Rahman F, Piekarz R et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther. 2010;10(7):997\u20131008. https:\/\/doi.org\/10.1586\/era.10.88. Erratum in: Expert Rev Anticancer Ther. 2011;11(10):1622.","DOI":"10.1586\/era.10.88"},{"key":"1646_CR113","unstructured":"Multicentre 4SCAGA, Blind D, Randomised, Placebo-Controlled. Phase II trial to evaluate resminostat for maintenance treatment of patients with Advanced Stage (stage IIB-IVB) mycosis fungoides (MF) or S\u00e9zary Syndrome (SS) that have achieved Disease Control with systemic therapy - the RESMAIN Study. https:\/\/clinicaltrials.gov\/study\/NCT02953301 (2023)."},{"issue":"2","key":"1646_CR114","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/cancers12020265","volume":"12","author":"S Ito","year":"2020","unstructured":"Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel). 2020;12(2):265. https:\/\/doi.org\/10.3390\/cancers12020265.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1646_CR115","first-page":"433","volume":"3","author":"TP Chang","year":"2013","unstructured":"Chang TP, Vancurova I. NF\u03baB function and regulation in cutaneous T-cell lymphoma. Am J Cancer Res. 2013;3(5):433\u201345.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"1646_CR116","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.4049\/jimmunol.1402610","volume":"194","author":"TP Chang","year":"2015","unstructured":"Chang TP, Poltoratsky V, Vancurova I. Bortezomib inhibits expression of TGF-\u03b21, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells. J Immunol. 2015;194(6):2942\u201353. https:\/\/doi.org\/10.4049\/jimmunol.1402610.","journal-title":"J Immunol"},{"issue":"6","key":"1646_CR117","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1600-0609.2009.01239.x","volume":"82","author":"U Heider","year":"2009","unstructured":"Heider U, Rademacher J, Lamottke B, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Haematol. 2009;82(6):440\u20139. https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01239.x.","journal-title":"Eur J Haematol"},{"issue":"27","key":"1646_CR118","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","volume":"25","author":"PL Zinzani","year":"2007","unstructured":"Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27):4293\u20137. https:\/\/doi.org\/10.1200\/JCO.2007.11.4207.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1646_CR119","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1080\/10428194.2016.1276287","volume":"58","author":"B Holkova","year":"2017","unstructured":"Holkova B, Yazbeck V, Kmieciak M, et al. A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma. 2017;58(6):1349\u201357. https:\/\/doi.org\/10.1080\/10428194.2016.1276287.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1646_CR120","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jdcr.2020.01.015","volume":"6","author":"AJ Tschetter","year":"2020","unstructured":"Tschetter AJ, Zafar F, Moye MS, et al. CD20\u2009+\u2009cutaneous T-cell lymphoma with phenotypic shift after treatment with rituximab: case report and review of the literature. JAAD Case Rep. 2020;6(4):308\u201310. https:\/\/doi.org\/10.1016\/j.jdcr.2020.01.015.","journal-title":"JAAD Case Rep"},{"issue":"9","key":"1646_CR121","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1182\/blood.2022018669","volume":"142","author":"JP Nicolay","year":"2023","unstructured":"Nicolay JP, Melchers S, Albrecht JD, et al. Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study. Blood. 2023;142(9):794\u2013805. https:\/\/doi.org\/10.1182\/blood.2022018669.","journal-title":"Blood"},{"issue":"8","key":"1646_CR122","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood-2013-09-525915","volume":"123","author":"C Querfeld","year":"2014","unstructured":"Querfeld C, Rosen ST, Guitart J, et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and S\u00e9zary syndrome. Blood. 2014;123(8):1159\u201366. https:\/\/doi.org\/10.1182\/blood-2013-09-525915.","journal-title":"Blood"},{"issue":"5","key":"1646_CR123","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3390\/cancers16050861","volume":"16","author":"SM Vahabi","year":"2024","unstructured":"Vahabi SM, Bahramian S, Esmaeili F, et al. JAK inhibitors in cutaneous T-Cell lymphoma: friend or foe? A systematic review of the published literature. Cancers (Basel). 2024;16(5):861. https:\/\/doi.org\/10.3390\/cancers16050861.","journal-title":"Cancers (Basel)"},{"key":"1646_CR124","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1756-8722-6-90","volume":"6","author":"M Furqan","year":"2013","unstructured":"Furqan M, Akinleye A, Mukhi N, et al. STAT inhibitors for cancer therapy. J Hematol Oncol. 2013;6:90. https:\/\/doi.org\/10.1186\/1756-8722-6-90.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1646_CR125","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3390\/cells10061270","volume":"10","author":"JN Lichterman","year":"2021","unstructured":"Lichterman JN, Reddy SM. Mast cells: a New Frontier for Cancer Immunotherapy. Cells. 2021;10(6):1270. https:\/\/doi.org\/10.3390\/cells10061270.","journal-title":"Cells"},{"key":"1646_CR126","doi-asserted-by":"publisher","first-page":"968395","DOI":"10.3389\/fimmu.2022.968395","volume":"13","author":"V To","year":"2022","unstructured":"To V, Evtimov VJ, Jenkin G, et al. CAR-T cell development for cutaneous T cell lymphoma: current limitations and potential treatment strategies. Front Immunol. 2022;13:968395. https:\/\/doi.org\/10.3389\/fimmu.2022.968395.","journal-title":"Front Immunol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01646-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01646-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01646-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:09:49Z","timestamp":1757142589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01646-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":126,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01646-6","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"30 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}